CIPROFLOXACIN
| Brand name | OTIPRIO |
|---|---|
| Active ingredient | CIPROFLOXACIN |
| Strength | 6% (60MG/ML) |
| Dosage form | INJECTABLE, SUSPENSION |
| Route | OTIC |
| Modality | Small molecule |
| FDA approval | December 2015 |
| Marketing status | DISCN |
| Patent | Expires | Type |
|---|---|---|
| 11246863 | November 2038 | product |
| 11040004 | November 2037 | use U-2252 |
| 9220796 | July 2035 | product |
| 8318817 | April 2030 | use U-1792 |
| 9233068 | December 2029 | product |
| 9205048 | April 2029 | use U-1793 |
| 11369566 | April 2029 | product |
| 9603796 | April 2029 | substance, product |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.